Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04777617 · ClinicalTrials.gov registry record
Allosure in Simultaneous Pancreas Kidney Transplant
A clinical trial, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- 13
- Enrollment target
NCT04777617: Clinical Trial study, sponsored by Washington University School of Medicine.
NCT04777617 is a clinical trial that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04777617 was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This study will observe donor derived cell free DNA percentages (via the Allosure test) in combined kidney-pancreas transplant recipients to establish both stable and dysfunctional Allosure assay levels
Primary Outcome
determine level of donor derived cell free DNA from SPK patients
Interventions
- OTHER DD-cfDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2024-07-31 |
Why NCT04777617 stopped before completion
NCT04777617 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DD-cfDNA is the first listed.
NCT04777617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04777617 about?
NCT04777617 is a clinical study titled "Allosure in Simultaneous Pancreas Kidney Transplant". This study will observe donor derived cell free DNA percentages (via the Allosure test) in combined kidney-pancreas transplant recipients to establish both stable and dysfunctional Allosure assay levels
What is the current status of trial NCT04777617?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2021-02-26. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT04777617?
The interventions under investigation include: DD-cfDNA (OTHER).
Who is sponsoring clinical trial NCT04777617?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI